Fulcrum Therapeutics, Inc. (FULC) Earnings History

Fulcrum Therapeutics, Inc. - Q4 FY2025 Earnings

Filed at: Feb 24, 2026, 7:05 AM EST|Read from source

EXECUTIVE SUMMARY

Fulcrum Therapeutics reported positive 12-week data from its Phase 1b PIONEER trial for pociredir in sickle cell disease, showing significant fetal hemoglobin induction and improvements in related markers. The company ended the year with a strong cash position, extending its runway into 2029, and plans to initiate a registration-enabling trial in the second half of 2026.

POSITIVE HIGHLIGHTS

  • •

    Announced positive 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial in SCD, demonstrating mean absolute HbF increase of 12.2% from baseline to 19.3% at Week 12.

    positive
  • •

    Ended 2025 with $352.3 million in cash, cash equivalents, and marketable securities, providing a cash runway into 2029.

    positive
  • •

    Completed an underwritten public offering in December 2025, raising $164.2 million in net proceeds to support advancement of pociredir.

    positive
  • •

    Pociredir continued to be generally well-tolerated with no treatment-related serious adverse events reported.

    positive

CONCERNS & RISKS

  • •

    Net loss for the three months ended December 31, 2025, was $20.3 million, an increase from $16.6 million in the prior year period.

    negative
  • •

    Net loss for the full year ended December 31, 2025, was $74.9 million, a significant increase from $9.7 million in the prior year.

    negative
  • •

    Research and development expenses increased by $3.7 million for the three months ended December 31, 2025, compared to the prior year period, due to increased costs for the PIONEER trial.

    attention
  • •

    Decided not to advance its program for bone marrow failure syndromes into clinical development to focus resources on pociredir.

    attention

FINANCIAL METRICS

Revenue
Quarterly
N/A
N/A
Net Income
Quarterly
$-20.33M
-22.7%
Prior year: $-16.57M
Annual (YTD)
$-74.88M
N/A
Prior year: $-9.72M
EPS (Diluted)
Quarterly
$-0.31
0.0%
Prior year: $-0.31
Operating Income
Quarterly
$-22.69M
+16.8%
Prior year: $-19.43M
Annual (YTD)
$-84.77M
N/A
Prior year: $-21.90M
EPS (Basic)
Quarterly
$-0.31
0.0%
Prior year: $-0.31

MARGIN ANALYSIS

Operating Margin
Current Quarter
-100.0%
Prior Year
-100.0%
YoY Change
0 bps
Net Margin
Current Quarter
-100.0%
Prior Year
-100.0%
YoY Change
0 bps

Margin expansion indicates improving profitability and operational efficiency. Measured in basis points (bps): 100 bps = 1.0%.

MANAGEMENT COMMENTARY

Reinforce conviction in pociredir’s potential to address the underlying biology of sickle cell disease.

— Fulcrum Therapeutics, Inc., Q4 FY2025 2025 Earnings Call

Highlight magnitude of HbF induction, progression toward pan-cellular distribution, and improvements in markers of hemolysis and anemia.

— Fulcrum Therapeutics, Inc., Q4 FY2025 2025 Earnings Call

Positioned to address FDA regarding the design of the next study.

— Fulcrum Therapeutics, Inc., Q4 FY2025 2025 Earnings Call

Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.

OPERATIONAL METRICS

HbF At Week 12
19.3
%
HbF Induction
12.2
%
Baseline HbF
7.1
%

Operational metrics provide insight into business drivers and customer engagement beyond traditional financial measures.